President’s Donald Trump’s budget proposal should be treated as a genuine, credible threat to science, said Richard Klausner, a biotechnology entrepreneur who led NCI through the years of the doubling of the NIH budget.
How’s this for a paradox: The better cancer centers become at keeping patients alive, the more expensive cancer care becomes. This brutal tradeoff hits harder in rural areas, where the cancer burden is higher and the investigator and clinical trial representation is lower.
